Mobitz type II AV block, 337–338, 337f m-O-dealkyalted lactam (MODLF), 1437 m-O-dealkylated flecainide (MODF), 1437 Modified Blalock-Taussig shunt, 1278–1279, 1278f Modified Fontan procedure, 1300–1304, 1300b decision making in, 1301–1303 postoperative considerations in, 1303–1304, 1303b bedside preparedness and monitoring, 1303 effusions/chylothorax, 1304 low cardiac output in, 1303–1304, 1304t positive-pressure ventilation, 1303 rhythm disturbances, 1304 preoperative evaluation in, 1300, 1300t surgical strategies in, 1300–1301, 1301f–1302f Monogenic syndromes, 1412–1419 Adams-Oliver syndrome, 1417, 1417t Alagille syndrome, 1416, 1416t Charge syndrome, 1417, 1417t Ellis-van Creveld syndrome, 1414–1415, 1414f, 1414t Goldenhar syndrome, 1418–1419, 1418t Holt-Oram syndrome, 1416–1417, 1416f, 1416t Kabuki syndrome, 1415–1416, 1415f, 1415t RASopathies (Noonan syndrome and related disorders), 1412–1414, 1413f, 1413t VACTERL association, 1417, 1418f, 1418t Monomorphic ventricular tachycardia, 350–351, 351f Moral distress, 1474–1475, 1475b Moral diversity, cultural and, 1471, 1471t Moral resilience, 1474–1475, 1475b key characteristics of, 1475b Morphologic method, 441 Morquio syndrome, cardiac involvement in, 1091 Mortality following transplantation, 1218–1219, 1222f–1224f causes of death and, 1221, 1225t, 1226f risk factors for death and, 1219–1220, 1224t–1225t in Fontan circulation, for univentricular heart, 1318 neonatal according to birth, 190t in prematurity, 211 rate, definition of, 190b while awaiting cardiac transplantation, 1217–1218 Mother, optimizing prenatal support of, 163–170 Mouse myocardial development, 61, 62f MRI, Magnetic resonance imaging Mucocutaneous lymph node syndrome, 979 Mucolipidoses, cardiac involvement in, 1091–1092 Mucopolysaccharidoses, cardiac involvement in, 1089–1091 MUGA, Multigated radionuclide angiography Multicenter Pediatric and Adult Congenital EP Quality Registry, 1511t–1514t Multidisciplinary team, 1481 Multidistribution circulation, 1264 Multidrug resistance, 1528 Multifocal atrial tachycardia (MAT), 349, 349f Multigated radionuclide angiography (MUGA), for cancer therapy-related cardiotoxicity, 1171 Multitrack system, 1035, 1036t Murmurs in Ebstein malformation, 591 in interatrial communication, 511 Muscle phosphofructokinase 1 deficiency, cardiac involvement in, 1089 Muscle phosphorylase deficiency, cardiac involvement in, 1089 Muscular dystrophies, cardiac involvement in, 1102–1105 Mustard procedure, for transposition of the great arteries, 686 Myocardial activation, in cardiac myocyte, 1197 Myocardial bridging, 869 Myocardial development, 59–82 cell biology with human disease, 77–82 Barth syndrome (BTHS), 80–81 Danon disease (DD), 80 Duchenne muscular dystrophy, 77–80, 78f hypertrophic cardiomyopathy, 77 precision medicine in, 81–82 cell types in, 62–66 cardiomyocyte, 62, 63f endothelial cells, 65–66 fibroblasts, 62–64, 63f–64f vascular smooth muscle cells, 64–65, 65f early, 59–62 atrial and ventricular septation in, 60–61 atrioventricular valves formation in, 61 cardiac looping in, 59–60, 60f human and mouse, comparison of, 61, 62f outflow tract and semilunar valve development in, 61 structural heart disease origin in, 61–62 regeneration, 66–67 Myocardial dysfunction, in prematurity, 201 Myocardial fibrosis, 450 Myocardial function, regulation of, prematurity and, 191–192 Myocardial infarction, 450 in Kawasaki disease, 984 premature, systemic arterial dysfunction and, 1371 Myocardial ischemia, evaluation of, exercise testing for, 391, 394 Myocardial protection, in cardiopulmonary bypass, 230 Myocarditis, 1173–1178, 1522–1523 autoimmune, 1178 autoinflammatory, 1178 cardiac magnetic resonance in, 1175, 1177f ... Mucopolysaccharidoses, cardiac involvement in, 1089–1091 MUGA, Multigated radionuclide angiography Multicenter Pediatric and Adult Congenital EP Quality Registry, 1511t–1514t Multidisciplinary team, 1481 Multidistribution circulation, 1264